Analysts Anticipate Vericel Co. (NASDAQ:VCEL) Will Announce Quarterly Sales of $33.86 Million

Wall Street brokerages predict that Vericel Co. (NASDAQ:VCELGet Rating) will post sales of $33.86 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Vericel’s earnings. The highest sales estimate is $34.34 million and the lowest is $33.00 million. Vericel reported sales of $34.57 million in the same quarter last year, which would indicate a negative year over year growth rate of 2.1%. The firm is expected to report its next earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Vericel will report full year sales of $184.01 million for the current financial year, with estimates ranging from $182.52 million to $185.38 million. For the next year, analysts anticipate that the firm will report sales of $227.64 million, with estimates ranging from $220.41 million to $233.12 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Vericel.

Vericel (NASDAQ:VCELGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The biotechnology company reported $0.09 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.17 by ($0.08). The company had revenue of $47.60 million for the quarter, compared to analysts’ expectations of $48.09 million. Vericel had a negative net margin of 4.78% and a negative return on equity of 4.83%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.25 earnings per share.

VCEL has been the subject of a number of analyst reports. TheStreet downgraded Vericel from a “c-” rating to a “d+” rating in a research note on Thursday, March 31st. StockNews.com initiated coverage on Vericel in a research note on Thursday, March 31st. They set a “sell” rating for the company. Zacks Investment Research downgraded Vericel from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 12th. Finally, SVB Leerink increased their target price on Vericel from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Friday, February 25th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $54.00.

VCEL opened at $35.40 on Friday. The company has a market cap of $1.66 billion, a PE ratio of -208.24 and a beta of 1.87. The business has a 50 day moving average price of $36.83 and a two-hundred day moving average price of $39.43. Vericel has a 52 week low of $30.67 and a 52 week high of $68.94.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its holdings in shares of Vericel by 10.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,020 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 277 shares during the period. Maryland State Retirement & Pension System grew its holdings in shares of Vericel by 1.7% in the 4th quarter. Maryland State Retirement & Pension System now owns 18,663 shares of the biotechnology company’s stock worth $733,000 after acquiring an additional 315 shares during the period. Millennium Management LLC grew its holdings in shares of Vericel by 2.0% in the 4th quarter. Millennium Management LLC now owns 15,938 shares of the biotechnology company’s stock worth $626,000 after acquiring an additional 318 shares during the period. Thrivent Financial for Lutherans grew its holdings in shares of Vericel by 1.1% in the 4th quarter. Thrivent Financial for Lutherans now owns 38,099 shares of the biotechnology company’s stock worth $1,497,000 after acquiring an additional 407 shares during the period. Finally, Gotham Asset Management LLC grew its holdings in Vericel by 4.5% during the 3rd quarter. Gotham Asset Management LLC now owns 9,573 shares of the biotechnology company’s stock valued at $467,000 after buying an additional 415 shares during the last quarter.

Vericel Company Profile (Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

See Also

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.